Who
David Kirske
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, X4 Pharmaceuticals; EVP, Chief Financial Officer, Cti Biopharma.
In numbers
- Trades disclosed
- 81
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $2.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Aug 2017
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $34K11,767 at $2.86 | filing |
| 30 Jun 2026filed 1 Jul 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36K8,543 at $4.26 | filing |
| 30 Jun 2026filed 1 Jul 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36K8,543 at $4.26 | filing |
| 12 May 2026filed 13 May 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K16,961 at $4.29 | filing |
| 12 May 2026filed 13 May 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K16,961 at $4.29 | filing |
| 29 Oct 2025filed 31 Oct 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,552,769 at $0.00 | filing |
| 14 Aug 2025filed 14 Aug 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —352,800 at $0.00 | filing |
| 14 Aug 2025filed 14 Aug 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —193,254 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,073,249 at $0.00 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —315,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —83,396 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —270,216 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —340,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —280,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharma | SEC FORM 4 Code U | $160K17,547 at $9.10 | filing |
| 14 Mar 2023filed 16 Mar 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Jan 2023filed 3 Jan 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code M | —27,021 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.